Back

Epigenetic signatures and cardiovascular risk in diabetes.

27 August 2018 (11:00 - 11:22)
Organised by:
Congress Presentation Part of: How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease? Metabolic Syndrome, Insulin, Insulin Resistance ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Francesco Cosentino

Karolinska University Hospital, Stockholm (Sweden)

3 More presentations in this session

Presentation thumbnail
Use of incretin-based therapies.
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
Mechanisms of cardiovascular impact of SGLT2 inhibitors.
Professor B. Staels (Lille Cedex, FR)
Slides Video
Presentation thumbnail
SGLT2 inhibitors and alteration of substrate metabolism.
Professor E. Ferrannini (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

The Event

Event poster

ESC Congress 2018

27 August 2018 11:00 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources